Srdan Verstovsek, MD, on the Phase III VERIFY Trial
By Leah Sherwood, Srdan Verstovsek, MD, PhD - Last Updated: May 30, 2023Srdan Verstovsek, MD, of the University of Texas MD Anderson Cancer Center discusses the phase III VERIFY trial of the hepcidin mimetic rusfertide in patients with polycythemia vera.
Advertisement
Post Tags:ASH22
Advertisement
Related Posts
Dr. Shah discusses the significance and limitations of two studies on dietary factors and risk of myeloma and MGUS.
A plant-based diet is significantly associated with a reduced risk of multiple myeloma.
A US population-based study investigated the associations between MGUS and various dietary patterns.
The expert panel describes outstanding clinical research needs in DLBCL and what research underway they find exciting.
Expert clinicians describe which factors they consider when selecting between these two interventions for DLBCL management.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.